IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Zacks News
HOLX vs. IDXX: Which Stock Is the Better Value Option?
by Zacks Equity Research
HOLX vs. IDXX: Which Stock Is the Better Value Option?
IDEXX OPTI Medical Gets CE Mark for RT-PCR Coronavirus Test
by Zacks Equity Research
This test by IDEXX (IDXX) benefits from an optimized workflow and claims to deliver greater assurance of quality and accuracy.
Idexx (IDXX) Up 11.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com featured highlights include: Myriad Genetics, Cinemark, Vericel and IDEXX Laboratories
by Zacks Equity Research
Zacks.com featured highlights include: Myriad Genetics, Cinemark, Vericel and IDEXX Laboratories
IDEXX Sees Higher Clinical Visits Despite Coronavirus Crisis
by Zacks Equity Research
IDEXX (IDXX) notes a significant improvement in U.S. clinical visit trends across major regions.
Dump These 4 Toxic Stocks or Sell Short for Timely Profits
by Zacks Equity Research
Identifying toxic stocks and discarding them at the right time is the key to guard your portfolio from big losses.
IDEXX (IDXX) Q1 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
IDEXX Laboratories (IDXX) companion animal clinical visits decrease due to the impact of the coronavirus pandemic.
Idexx Laboratories (IDXX) Beats Q1 Earnings Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 4.88% and -0.86%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Earnings on Apr 30: BAX, IDXX & More
by Zacks Equity Research
The medical product companies have partially mitigated the impact of the pandemic driven by the massive adoption of COVID-19 related healthcare-support products and services.
Idexx Laboratories (IDXX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for IDEXX Laboratories (IDXX) in Q1 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) business is likely to have benefited from few cases in which pets were found to be COVID-19 positive globally.
Coronavirus Hits S&P 500: 4 MedTech Stocks That Fared Better
by Zacks Equity Research
Here are a few MedTech companies which have outperformed the S&P 500 index in the past two months.
IDEXX's (IDXX) CAG Arm Grows Strong on Product Launches
by Zacks Equity Research
Product launches like Cornerstone, Neo, Animana aid IDEXX' (IDXX) CAG business.
Masimo's Latest Buyout to Boost Respiratory Product Spectrum
by Zacks Equity Research
Masimo (MASI) expects the transaction to be neutral to 2020 earnings.
Here's Why You Should Hold Onto Baxter (BAX) Stock for Now
by Zacks Equity Research
Baxter (BAX) issues strong guidance for the first quarter of 2020.
Varian's (VAR) ProBeam Compact Treats First Patient at UAB
by Zacks Equity Research
Varian's (VAR) flagship ProBeam platform is seeing multiple developments of late.
HealthEquity (HQY) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
HealthEquity's (HQY) fiscal fourth-quarter earnings benefit from higher revenues and solid performing Service, Custodial and Interchange segments.
Baxter (BAX) Q4 Earnings Beat Estimates, Revenues In Line
by Zacks Equity Research
Baxter's (BAX) fourth-quarter earnings benefit from higher revenues, solid segmental performance and growth in APAC.
Here's Why You Should Hold Onto Varian Medical Stock Now
by Zacks Equity Research
Varian Medical (VAR) gains from solid prospects of its core Oncology Systems unit.
Here's Why You Should Buy Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) lifts adjusted earnings per share view for fiscal 2020.
Cooper Companies (COO) Misses on Q1 Earnings, Lifts View
by Zacks Equity Research
Cooper Companies (COO) gains from core CVI segment in fiscal Q1.
5 Must-Buy S&P 500 Large-Cap Growth Stocks at a Discount
by Nalak Das
As a result of regular market fluctuations, several growth stocks have become ultra-cheap at present, some of which have strong growth potential.
Allscripts (MDRX) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Allscripts (MDRX) fourth-quarter results gain from higher revenues along with growth in bookings. Contraction in both gross and operating margins remains a woe.
Veeva Systems (VEEV) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Veeva Systems (VEEV) gains from segmental strength in the fiscal fourth quarter.
Here's Why You Should Hold Avanos Medical (AVNS) Stock Now
by Zacks Equity Research
Avanos (AVNS) gains from solid fourth-quarter show despite headwinds in the Acute Pain business.